Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings

Rheumatology

Volumn 43, Issue 3, 2004, Pages 272-276

  Myers, Andrea ^b   Lakey, R ^b   Cawston, T E ^b   Kay, L J ^a   Walker, D J ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Matrix metalloproteinases; Psoriasis; Psoriatic arthritis; Tissue inhibitor metalloproteinases

Indexed keywords

INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD DONOR; BONE DESTRUCTION; CONTROLLED STUDY; DISTAL PHALANX; ENTHESITIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SIBLING; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE;

ADULT; AGE OF ONSET; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PSORIASIS; SIBLINGS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 1542329584     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh032     Document Type: Article

References (32)

1. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996;70:163-82.
2. Ito A, Nagase H. Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys 1988;267:211-6.
3. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJP. Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes. Biochem J 1987;248:265-8.
4. Brinckerhoff CE, Auble DT. Regulation of collagenase gene expression in synovial fibroblasts. Ann NY Acad Sci 1990;580:355-74.
5. Goldring M. Degradation of articular cartilage in culture: regulatory factors. In: Woessner JF, Howell DS, eds. Joint cartilage degradation. New York: Marcel Dekker, 1993:281-346.
6. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
7. MacNaul KL, Chartrain N, Lark M et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J Biol Chem 1990;265:17238-45.
8. Martel-Pelletier J, McCollum R, Fujimoto N et al. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
9. Gravallese EM, Darling JM, Ladd AL et al. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
10. Walakovits LA, Moore VA, Bhardwaj N et al. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraurnatic knee injury. Arthritis Rheum 1992;35:35-42.
11. Clark IM, Powell LK, Wright JK, Cawston TE, Hazelman BL. Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase. Matrix 1992;12:475-80.
12. Brennan FM, Browne KA, Green PA et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
13. Clark IM, Powell LK, Ramsey S, Hazelman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinase (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993;36:372-9.
14. Partsch G, Petera P, Leeb L et al. High free and latent collagenase activity in psoriatic arthritis synovial fluids. Br J Rheum 1994;33:702-6.
15. Cawston TE, Clark IM, Hazelman BL. High free and latent collagenase activity in psoriatic arthritis synovial fluids [letter]. Br J Rheum 1995;34:83-92.
16. Ribbens C, Andre B, Kaye O et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology 2000;39:1357-65.
17. Ribbens C, Martin y Porras M, Franchimont N et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
18. Clark IM, Powell EK, Wright JK, Cawston TE. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991;11:76-85.
19. Yoshihara Y, Obata K, Fujimoto N et al. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969 75.
20. Khandke L, Krane JF, Ashinoff R et al. Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor α/ epidermal growth factor receptor pathways. Arch Dermatol 1991;127:1172-9.
21. Gillitzer R, Berger R, Mielke V et al. Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/ IL-8 mRNA in situ. J Invest Dermatol 1991;97:71-79.
22. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990;94(Suppl):135S-140S.
23. Ohta Y, Katayama I, Funato T et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res 1991;283:351-6.
24. Gottlieb AB. Immunologic mechanisms in psoriasis. J Invest Dermatol 1990;95(Suppl):18S-19S.
25. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
26. Dinarello CA, Moldawer LL. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. California, USA: Amgen Publishing, 2002.
27. Dinant HJ, Dijkmans BA. New therapeutic targets for rheumatoid arthritis. Pharm World Sci 1999;21:49-59.
28. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
29. Henseler T, Christophers M. Psoriasis of early and late onset: characteristics of the two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.
30. Plumpton TA, Clark IM, Plumpton C, Calvin J, Cawston TE. Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP-1 and CRP in serum. Clin Chimica Acta 1995;240:137-54.
31. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8.
32. Manicourt DH, Fujimoto N, Obata K, Thonar E. Levels of circulating collagenase, stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:1031-9.